Screener
Bristol-Myers Squibb BMY Proceeds from Issuance of Commercial Paper
Proceeds from Issuance of Commercial Paper at other companies
Other financials
Where this comes from
Reported directly by Bristol-Myers Squibb in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommercialPaper.
The source filing: Bristol-Myers Squibb’s 10-K, filed February 11, 2026.
- Filed
- Feb 10, 2026, 7:00 PM EST
- Fiscal year
- FY2025
- Accession
- 0000014272-26-000004
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 | Year Ended December 31, 2023 |
|---|---|---|---|
| Acquisition and other payments, net of cash acquired | (3,944) | (21,821) | (1,169) |
| Net cash provided by/(used in) investing activities | (4,132) | (21,352) | (2,295) |
| Cash Flows From Financing Activities: | |||
| Proceeds from issuance of short-term debt obligations | — | 2,987 | — |
| Repayments of short-term debt obligations | — | (3,000) | — |
| Other short-term financing obligations, net | 25 | 99 | (120) |
| Proceeds from issuance of long-term debt | 5,740 | 12,883 | 4,455 |
| Repayments of long-term debt | (10,940) | (2,873) | (3,879) |
Item 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.
FAQ
- What is Bristol-Myers Squibb's proceeds from issuance of commercial paper?
- Bristol-Myers Squibb (BMY) reported proceeds from issuance of commercial paper of $0 in Q4 2025.
- What does proceeds from issuance of commercial paper mean?
- This represents cash raised through the issuance of short-term, unsecured promissory notes used to manage immediate working capital needs. It is a common tool for bridging temporary cash flow gaps or managing seasonal fluctuations in operational requirements. It reflects the company's short-term credit market access.
Ask your AI about Bristol-Myers Squibb's proceeds from issuance of commercial paper.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude